Found 183 results in Expert Content

Summary: Dramatically shifting the attention of the industry, Covid-19 forced orphan developers to re-examine their go-to-market strategies.

Summary: Low bioavailability can lead to development challenges. Advanced formulation expertise and technologies can increase the chance of success in the clinic.

Summary: Jeremy Trochu, Vice President and General Manager of Pharmaceutical Development Services at Catalent, recently sat down for an interview...

Summary: Big Pharma used to ignore this segment of the market, but now developing orphan drugs to treat these rare diseases is an industry priority.

Summary: In this report, we will highlight the trends shaping the orphan-drug market, with a particular focus on expedited drug development. Expert insights on navigating development and manufacturing challenges with...

Summary: Explore how you can leverage Catalent’s successful track record optimizing thousands of molecules, deep development expertise and broadest set of superior technologies to...

Summary: Catalent offers end-to-end spray drying solutions from early-phase development through to clinical supply, and scale-up to commercial finished dose forms.

Summary: A fast, efficient development process can deliver the right clinical candidate, best formulation strategy, and optimal dosage form to Phase 1.

Summary: This webinar focuses on the key considerations for transitioning small molecules from preclinical through clinical development.

Summary: Achieving success in early development is essential in progressing a drug molecule’s next milestone. Such pressure can often lead to the adoption of...